FOR IMMEDIATE RELEASE

BioFire Diagnostics, Inc. Names Robert Lollini Chief Financial Officer

Twenty Five Years of Healthcare and Financial Management Experience

SALT LAKE CITY, (November 01, 2012) - BioFire Diagnostics, Inc. today announced the appointment of Robert Lollini as its Chief Financial Officer. Mr. Lollini most recently served as Chief Executive Officer and formerly Chief Financial Officer of Myrexis, Inc., a Utah-based biotechnology company.

Carl Wittwer, MD, PhD, Chairman of the Board of BioFire Diagnostics, commented, "We welcome Bob to BioFire. His in-depth experience with high growth healthcare companies, capital markets and financial management will contribute significantly to the Company and the management team as we continue to strengthen our industry position in the molecular diagnostic arena."

Kirk Ririe, Chief Executive Officer of BioFire, added, "We are quite fortunate to have attracted Bob to BioFire with his strong track record in strategic financial and executive management with high growth healthcare companies. He will play an integral role in developing and implementing our strategy to ensure BioFire is in strong position to continue on its growth trajectory."

Mr. Lollini remarked, "This is an ideal opportunity for me. My background in the planning and implementation of strategic financing initiatives corresponds with those that BioFire currently has underway to finance its growth. BioFire's FDA cleared respiratory panel, coupled with its FilmArray[®] molecular diagnostics platform, represents a significant a technological advancement and commercial opportunity. I am very happy to be part of the BioFire team."

Prior to joining BioFire, Mr. Lollini held executive management positions at Myrexis, Inc., a NASDAQ-listed biotechnology company, inclusive of Chief Financial Officer from 2009 to 2011 and Chief Executive Officer through 2012, and remains a member of its Board of Directors. Between 1993 and 2007, he held multiple executive positions at lomed, Inc. an AMEX-traded international drug delivery company that was acquired in May 2007. Earlier in his career, he held various executive management positions at R.P. Scherer Corporation, an international developer and manufacturer of oral drug delivery systems. Mr. Lollini started his professional career with the accounting firm of Arthur Anderson & Co. Mr. Lollini is a Certified Public Accountant and received a Bachelor of Arts degree in Accounting from Michigan State University and an MBA in Finance/Economics from the University of Detroit Mercy.

About BioFire Diagnostics, Inc.

BioFire Diagnostics, Inc., formerly Idaho Technology, Inc., is a privately held clinical diagnostics company based in Salt Lake City, Utah. The Company manufactures and distributes the FilmArray RP, which operates on the user-friendly FilmArray system, to hospital-based clinical laboratories across the U.S. and EU. With the FilmArray RP, BioFire provides the only FDA-cleared clinical diagnostic test for eight of the 20 organisms in its panel. In addition, BioFire continues to broaden its FilmArray test menu, and is currently developing a blood culture ID panel, a gastrointestinal panel, and a meningitis panel.

BioFire holds over 70 patents related to polymerase chain reaction (PCR), and it has used its extensive patent portfolio to successfully market nearly 200 products to the clinical, research, and military markets. BioFire customers include the Department of Health and Human Services, the Department of Defense, state and local law enforcement, and researchers and medical technicians across a spectrum of fields and industries.

For further information, please visit www.BioFireDx.com. Contact:

Idaho Technology is now



FOR IMMEDIATE RELEASE

BioFire Diagnostics, Inc.

Eric Gorrell (investor relations) General Counsel 801-736-6354 x803 Eric@biofiredx.com

The Ruth Group (on behalf of BioFire Diagnostics)
Carol Ruth or Nick Laudico
646-536-7004 / 7030
cruth@theruthgroup.com
nlaudico@theruthgroup.com

###

